Ultragenyx Pharmaceutical Sued for Alleged Misrepresentation in Setrusumab Clinical Trials

Ultragenyx Pharmaceutical Faces Class Action Lawsuit Over Misrepresentation in Clinical Trials

In a significant development for Ultragenyx Pharmaceutical Inc., the Rosen Law Firm announces a class action lawsuit regarding alleged misrepresentations in the company's clinical trials for setrusumab (UX 143), aimed at treating Osteogenesis Imperfecta. Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, are reminded that they have until April 6, 2026, to apply as lead plaintiffs in the case. The lawsuit claims that Ultragenyx overstated the effectiveness of setrusumab based on its Phase III Orbit and Cosmic Studies, particularly in relation to its impact on the annualized fracture rate for patients.

The allegations suggest that while Ultragenyx expressed strong confidence in the results and the integrity of the study designs, critical information pertinent to the drug's efficacy was withheld from investors. This omission raises significant concerns about transparency and ethical standards in clinical trial reporting, especially given the seriousness of Osteogenesis Imperfecta, a condition that requires effective treatment options. As stakeholders scrutinize the developments surrounding the lawsuit, the outcome may have far-reaching implications not only for Ultragenyx but also for similar biopharmaceutical companies that rely on investor trust in clinical data.

As the class action progresses, the Rosen Law Firm's longstanding history in securities class action cases comes under the spotlight. Known for its impactful settlements, the firm has recovered hundreds of millions for investors, reinforcing its reputation as a leader in this niche of investor rights advocacy. Founding partner Laurence Rosen's recognition by Law360 as a Titan of Plaintiffs' Bar only amplifies the firm's authority in navigating complex legal actions against public companies.

In related news, the Rosen Law Firm indicates that those interested in participating in the class action can register via their website or contact the firm directly. The deadline for becoming a lead plaintiff is crucial for affected investors seeking compensation without any upfront costs, given the firm's contingency fee structure. As this case unfolds, its ramifications could influence investors’ confidence in the biopharmaceutical sector, particularly regarding the accuracy of clinical trial communications.